Homologous prime boosting based on intranasal delivery of non-pathogenic invasive Escherichia coli expressing MPT64, decreases Mycobacterium tuberculosis dissemination

Vaccine

Volumn 32, Issue 32, 2014, Pages 4051-4058

  Sali, Michela ^a   Dainese, Elisa ^b   Morandi, Matteo ^a   Zumbo, Antonella ^a   Rocca, Stefano ^c   Goussard, Sylvie ^d   Palù, Giorgio ^b   Grillot Courvalin, Catherine ^d   Delogu, Giovanni ^a   Manganelli, Riccardo ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

^d INSTITUT PASTEUR   (France)

Author keywords

Attenuated vaccines: Mycobacterium tuberculosis; Bactofection; Tuberculosis

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VECTOR; BCG VACCINE; LIVE VACCINE; MPT64 ANTIGEN; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM TUBERCULOSIS PROTEIN; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; MPT64 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BCG VACCINATION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOPLASM; ESCHERICHIA COLI; EUKARYOTIC CELL; FEMALE; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SUBUNIT; TUBERCULOSIS; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; HELA CELL LINE; IMMUNIZATION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MICROBIOLOGY; PROCEDURES; SPLEEN;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL LOAD; BCG VACCINE; ESCHERICHIA COLI; FEMALE; HELA CELLS; HUMANS; IMMUNIZATION, SECONDARY; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT PROTEINS; SPLEEN; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84902549798     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.060     Document Type: Article

References (47)

1. World Health Organization Global tuberculosis control: surveillance, planning, financing 2011, http://www.who.int/tb/publications/global_report/en/.
2. Cegielski J.P. Extensively drug-resistant tuberculosis: there must be some kind of way out of here. Clin Infect Dis 2010, 50(Suppl. 3):S195-S200.
3. Rowland K. Totally drug-resistant TB emerges in India. Nature 2012, 10.1038/nature.2012.9797.
4. Colditz G.A., Berkey C.S., Mosteller F., Brewer T.F., Wilson M.E., Burdick E., et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995, 96:29-35.
5. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. J Am Med Assoc 1994, 271:698-702.
6. Brennan M.J., Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinburgh) 2012, 92(Suppl. 1):S6-S13.
7. Delogu G., Fadda G. The quest for a new vaccine against tuberculosis. J Infect Dev Ctries 2009, 3:5-15.
8. Andersen P., Doherty T.M. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005, 3:656-662.
9. Kaufmann S.H. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010, 33:567-577.
10. Aagaard C., Hoang T.T., Izzo A., Billeskov E., Troudt J., Arnett K., et al. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS ONE 2009, 4:e5930.
11. Schoen C., Loeffler D.I., Frentzen A., Pilgrim S., Goebel W., Stritzker J. Listeria monocytogenes as novel carrier system for the development of live vaccines. Int J Med Microbiol 2008, 298:45-58.
12. Vecino W.H., Quanquin N.M., Martinez-Sobrido L., Fernandez-Sesma A., García-Sastre A., Jacobs W.R., et al. Mucosal immunization with attenuated Shigella flexneri harboring an influenza hemagglutinin DNA vaccine protects mice against a lethal influenza challenge. Virology 2004, 325:192-199.
13. Larsen M.D., Griesenbach U., Goussard S., Gruenert D.C., Geddes D.M., Scheule R.K., et al. Bactofection of lung epithelial cells in vitro and in vivo using a genetically modified Escherichia coli. Gene Ther 2008, 15:434-442.
14. Brun P., Zumbo A., Castagliuolo I., Delogu G., Manfrin F., Sali M., et al. Intranasal delivery of DNA encoding antigens of Mycobacterium tuberculosis by non-pathogenic invasive Escherichia coli. Vaccine 2008, 26:1934-1941.
15. Yin Y., Tian D., Jia Y., Gao Y., Fu H., Niu Z., et al. Attenuated Listeria monocytogenes, a Mycobacterium tuberculosis ESAT-6 antigen expression and delivery vector for inducing an immune response. Res Microbiol 2012, 163:540-549.
16. Juarez-Rodriguez M.D., Arteaga-Cortes L.T., Kader R., Curtiss R., Clark-Curtiss J.E. Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system. Infect Immun 2012, 80:798-814.
17. Sali M., Di Sante G., Cascioferro A., Zumbo A., Nicolò C., Donà V., et al. Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice. Infect Immun 2010, 78:5202-5213.
18. Delogu G., Howard A., Collins F.M., Morris S.L. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun 2000, 68:3097-3102.
19. Delogu G., Li A., Repique C., Collins F., Morris S.L. DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun 2002, 70:292-302.
20. Sali M., Clarizio S., Pusceddu C., Zumbo A., Pecorini G., Rocca S., et al. Evaluation of the anti-tuberculosis activity generated by different multigene DNA vaccine constructs. Microbes Infect 2008, 10:605-612.
21. Cascioferro A., Delogu G., Colone M., Sali M., Stringaro A., Arancia G., et al. PE is a functional domain responsible for protein translocation and localization on mycobacterial cell wall. Mol Microbiol 2007, 66:1536-1547.
22. Li Z., Howard A., Kelley C., Delogu G., Collins F., Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun 1999, 67:4780-4786.
23. Romano M., Huygen K. DNA vaccines against mycobacterial diseases. Expert Rev Vaccines 2009, 8:1237-1250.
24. You Q., Wu Y., Wu Y., Wei W., Wang C., Jiang D., et al. Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis. Int J Infect Dis 2012, 16:e816-e825.
25. Tanghe A., Denis O., Lambrecht B., Motte V., van den B.T., Huygen K. Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment. Infect Immun 2000, 68:3854-3860.
26. Kaufmann S.H. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011, 11:633-640.
27. Brennan M.J., Clagett B., Fitzgerald H., Chen V., Williams A., Izzo A.A., et al. Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine 2012, 30:2811-2823.
28. Rodrigues L.C., Pereira S.M., Cunha S.S., Genser B., Ichihara M.Y., de Brito S.C., et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005, 366:1290-1295.
29. Williams A., Hatch G.J., Clark S.O., Gooch K.E., Hatch K.A., Hall G.A., et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinburgh) 2005, 85:29-38.
30. Xing Z., McFarland C.T., Sallenave J.M., Izzo A., Wang J., McMurray D.N. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS ONE 2009, 4:e5856.
31. Vordermeier H.M., Villarreal-Ramos B., Cockle P.J., McAulay M., Rhodes S.G., Thacker T., et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 2009, 77:3364-3373.
32. Wilkinson K.A., Simsova M., Scholvinck E., Sebo P., Leclerc C., Vordermeier H.M., et al. Efficient Ex vivo stimulation of Mycobacterium tuberculosis-specific T cells by genetically detoxified Bordetella pertussis adenylate cyclase antigen toxoids. Infect Immun 2005, 73:2991-2998.
33. Juarez-Rodriguez M.D., Yang J., Kader R., Alamuri P., Curtiss R., Clark-Curtiss J.E. Live attenuated Salmonella vaccines displaying regulated delayed lysis and delayed antigen synthesis to confer protection against Mycobacterium tuberculosis. Infect Immun 2012, 80:815-831.
34. Huang J.M., Sali M., Leckenby M.W., Radford D.S., Huynh H.A., Delogu G., et al. Oral delivery of a DNA vaccine against tuberculosis using operator-repressor titration in a Salmonella enterica vector. Vaccine 2010, 28:7523-7528.
35. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic' S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 2000, 97:13853-13858.
36. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479.
37. Hinchey J., Lee S., Jeon B.Y., Basaraba R.J., Venkataswamy M.M., Chen B., et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 2007, 117:2279-2288.
38. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006, 24:3408-3419.
39. Hernandez P.R., Aguilar L.D., Smith I., Manganelli R. Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB/c mouse model of progressive pulmonary tuberculosis. Infect Immun 2010, 78:3168-3176.
40. Desel C., Dorhoi A., Bandermann S., Grode L., Eisele B., Kaufmann S.H., Recombinant B.C.G. δureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011, 204:1573-1584.
41. Morandi M., Sali M., Manganelli R., Delogu G. Exploiting the mycobacterial cell wall to design improved vaccines against tuberculosis. J Infect Dev Ctries 2013, 7:169-181.
42. Balasubramanian V., Wiegeshaus E.H., Taylor B.T., Smith D.W. Pathogenesis of tuberculosis: pathway to apical localization. Tuber Lung Dis 1994, 75:168-178.
43. Pethe K., Alonso S., Biet F., Delogu G., Brennan M.J., Locht C., et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 2001, 412:190-194.
44. Soares A.P., Kwong Chung C.K., Choice T. Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns. J Infect Dis 2013, 207:1084-1094.
45. Nandakumar S., Kannanganat S., Dobos K.M., Lucas M., Spencer J.S., Fang S., et al. O-mannosylation of the Mycobacterium tuberculosis adhesin Apa is crucial for T cell antigenicity during infection but is expendable for protection. PLoS Pathog 2013, 9:e1003705.
46. Comas I., Chakravartti J., Small P.M., Galagan J., Niemann S., Kremer K., et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010, 42:498-503.
47. Gagneux S. Host-pathogen coevolution in human tuberculosis. Philos Trans R Soc Lond B Biol Sci 2012, 367:850-859.